Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KMT2B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KMT2B (SET Domain) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View KMT2B Products |
| Gene Delivery | KMT2B Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. |
View KMT2B Products |
| Benchmark Ab | Anti-KMT2B Recombinant Antibody Recombinant positive control for ChIP-seq and Western Blot. |
View KMT2B Products |
| Validator | KMT2B siRNA Set For knockdown verification in functional assays. |
View KMT2B Products |
| Related Target A | WDR5 Essential WD-repeat protein cofactor required for KMT2B methyltransferase activity. |
View WDR5 Products |
| Related Target B | KMT2A Closely related homolog (MLL1); critical counter-screening target for selectivity. |
View KMT2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (selectivity vs KMT2A/C/D) | Homolog panel proteins strictly verified by mass spectrometry and sequence analysis. |
| Reconstitution of active COMPASS-like complexes | High-purity cofactor proteins (WDR5, RBBP5) available with guaranteed >95% purity. |
| Lack of reliable positive controls | Recombinant benchmark antibodies included for assay baseline validation. |
| High rate of false positives in small molecule screens | Sequence-verified siRNA sets included for target knockdown validation. |
Live KMT2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KMT2B therapeutics is intensifying, with major players shifting focus from broad-spectrum chromatin regulators to highly selective small-molecule inhibitors and targeted protein degraders (PROTACs). As first-generation epigenetic therapies reach the clinic, the next wave of R&0 is targeting the specific protein-protein interactions (PPI) between KMT2B and its core complex adapters, as well as addressing its critical role in childhood-onset dystonia (DYT28) and specific solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Ryvu Therapeutics, Kronos Bio | Solid Tumors, Leukemias | Binding Affinity Assay (Need high-purity KMT2B-WDR5 complex proteins) |
| PROTAC (Degraders) | Arvinas, Academic Labs | Endometrial Cancer, Glioblastoma | Degradation Kinetics (Need Lentivirus for stable reporter line construction) |
| Gene Therapy / Correction | Neuro-focused Biotechs | Dystonia-28 (DYT28) | Expression Rescue Validation (Need sequence-verified KMT2B ORF) |